Most notably, SV-HotSpot detected a peak of recurrent SVs primarily comprised of tandem duplications targeting a non-coding enhancer located at ~ 625 kb upstream of AR, a key driver of prostate cancer progression, treatment resistance, and metastasis10 (Fig. 3). This evidence concerns the gene AR and prostate cancer.